Febrile neutropenia in adult patients with solid tumours: A review of literature toward a rational and optimal management;Neutropénie fébrile chez le patient adulte atteint de tumeur solide: Revue de la littérature pour une gestion rationnelle et optimale

Bulletin du Cancer

Volumn 97, Issue 5, 2010, Pages 547-557

  Even, C ^a   Taillade, L ^a   Spano, J P ^a   Vignot, S ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antibiotherapy; Antiobioprophylaxy; Chemotherapy; Growth factor; Neutropenia

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTEROIDES; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; DISEASE ASSOCIATION; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FUSOBACTERIA; GRANULOCYTOSIS; HUMAN; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; SOLID TUMOR; ADULT; BACTERIAL INFECTION; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG CONTRAINDICATION; EMERGENCY; FEVER; METHODOLOGY; MICROBIOLOGY; NEOPLASM; NEUTROPENIA; RISK FACTOR;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EMERGENCIES; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; NEUTROPENIA; PROGNOSIS; RISK FACTORS;

EID: 77953051426     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1045     Document Type: Review

References (56)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infections in patients with acute leukaemia. Ann Int Med 1966; 64: 328-340
2. Schimpff SC, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 204: 1061-1065
3. Blot F, Cordonnier C, Buzin A, Nitenberg G, Schlemmer B, Bastuji-Garin S, et al. Severity of illness scores: are they useful in febrile neutropenic adult patients in hematology wards? A prospective multicenter study. Crit Care Med 2001; 29: 2125-2131 (Pubitemid 33063540)
4. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490-494
5. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259
6. Paul M, Gafter-Gvili A, Leibovici L, Bishara J, Levy I, Yaniv I, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Isr Med Assoc J 2007; 9: 424-429
7. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infections in granulocytopenic patients. Arch Intern Med 1975; 135: 715-719
8. Müller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28: 977-983 (Pubitemid 30262065)
9. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Inf Dis 2004; 39: 206-217 (Pubitemid 38971491)
10. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008; 36: 396-407. Epub 2008 Aug 30. (Review).
11. Prat C, Sancho JM, Dominguez J, Xicoy B, Gimenez M, Ferra C, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 2008; 49: 1752-1761
12. Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol 2009; 20 (Suppl 4) : 166-169
13. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two center validation of a prediction rule. J Clin Oncol 1992; 10: 316-322
14. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051 (Pubitemid 30644129)
15. Rolston KVI. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Inf Dis 1999; 29: 515-521
16. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al. A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-311 (Pubitemid 29350300)
17. Kern WV, Cometta A, DeBock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312-318
18. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007; 30 (Suppl 1) : S51-9. Epub 2007 Aug 8.
19. Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 2008;16:485-491 Epub 2007 Sep 25.
20. Baskaran ND, Gan GG, Adeeba K. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 2008; 87:563-569 Epub 2008 Apr 24.
21. Gayol Mdel C, Font A, Casas I, Estrada O, Domínguez MJ, Pedro-Botet ML. [Usefulness of the MASCC scale in the management of neutropenic fever induced by chemotherapy in patients with solid neoplasm.] Med Clin (Barc) 2009 ; 133: 296-299 Epub 2009 Apr 18. (Spanish)
22. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26: 606-611
23. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-242 (Pubitemid 34464753)
24. Behre G, Link H, Maschmeyer G, Meyer P, Paaz U, Wilhelm M, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol 1998; 3: 324-330
25. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-558 (Pubitemid 16052468)
26. Yamamura D, Gacalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacilline-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41: 1704-1708 (Pubitemid 27339871)
27. Paul M, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect Dis Clin North Am 2009; 23: 277-293
28. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-1301
29. Hughes WT, Amstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Inf Dis 2002; 34: 730-751 (Pubitemid 34194843)
30. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin tazobactam monotherapy. Clin Inf Dis 2003; 37: 382-389
31. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG, Levine AS, Deisseroth AB, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67: 194-200.
32. Crane L, Komskian S, Sauber A. Antibiotic therapy in febrile neutropenic patients: what is the optimum duration of therapy? [abstract]. In : program and abstracts of the 28th interscience conference on antimicrobial agents and chemotherapy (Los Angeles). Washington, DC: American Society for Microbiology, 1988.
33. Bash RO, Katz JA, Cash JV, Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994; 74: 189-196
34. Joshi JH, Schimpff SC, Tenney JH, Newman KA, de Jongh CA. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 1984; 76: 450-457
35. DeMarie S, Van den Broek PJ, Willemze R, van Furth R. Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis 1993; 12: 897-906. (Pubitemid 24025867)
36. Aquino VM, Tkaczewski I, Buchanan GR. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 1997; 25: 74-78 (Pubitemid 27293077)
37. Smith TC, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205
38. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-2453
39. Garcia-Carbonero R, Mayordomo JI, Tornmira MV, López-Brea M, Rueda A, Guillem V, et al. Granulocyte colony-stimulating factor in the treatment of high risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93: 31-38
40. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, IJacquy C, et al. Therapeutic use of granulocuye and granulocyte-macrophage colony-stimulating factors in febrile neutroopenic cancer patients: a systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10: 181-188 (Pubitemid 36056292)
41. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005; 23: 4198-4214 (Pubitemid 46211326)
42. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005; 10: 427-437 (Pubitemid 40993570)
43. Ray-Coquard I, Borg C, Bachelot T, Fayette J, Zufferey L, Guastalla JP, et al. Prognostic factors for febrile neutropenia. Bull Cancer 2006; 93: 501-506
44. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 2009; 20 (Suppl 4) : 162-165
45. De Jongh CA, Wade JC, Finley RS, Joshi JH, Aisner J, Wiernik PH, et al. Trimethoprim/sulfamethoxazole versus placebo: a double blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. J Clin Oncol 1983; 1: 302-307
46. Gualtieri RJ, Donowitz GR, Kaiser DL, Hess CE, Sande MA. Double blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 1983; 74: 599-607.
47. Pizzo PA, Robichaud KJ, Edwards BK, Schumaker C, Kramer BS, Johnson A. Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. J Pediatr 1983; 102: 125-133
48. Wade JC, de Jongh CA, Newman KA, Crowley J, Wiernik PH, Schimpff SC. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: Trimethoprim/sulfamethoxazole vs. nalidixic acid. J Infect Dis 1983; 147: 624-634
49. Wilson JM, Guiney DG. Failure of oral trimethoprim/sulfamethoxazole prophylaxis in acute leukaemia: isolation of resistant plasmids from strains of enterobacteria causing bacteriema. N Engl J Med 1982; 306: 16-20.
50. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Simple investigation in neutropenic individuals of the frequency of infection after chemotherapy ± antibiotic in a number of tumours (significant) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-998
51. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-987
52. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142 (12 Pt 1) : 979-95 Erratum in: Ann Intern Med. 2006 ; 144: 704.
53. Imran H, Tleyjeh IM, Arndt CA, Baddour LM, Erwin PJ, Tsigrelis C, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008; 27: 53-63. (Pubitemid 350197874)
54. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38: 681-687 (Pubitemid 24114001)
55. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia [letter]. N Engl J Med 1994; 330: 1240-1241 (Pubitemid 24122001)
56. Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007; 25: 4821-4828 (Pubitemid 350086487)